SCHEMBL13490514

SCHEMBL13490514

c1ccc(CN2CCCC(c3ccccn3)C2)cc1

nearest known ligand 0.58

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 3/20 0.58
CYP2C9 P11712 2/20 0.58
CYP2D6 P10635 2/20 0.57
CYP1A2 P05177 2/20 0.56
CYP2C19 P33261 1/20 0.56
ALDH1A1 P00352 1/20 0.56
DRD4 P21917 2/20 0.52
DRD2 P14416 2/20 0.51
DRD3 P35462 1/20 0.51
HPGDS O60760 1/20 0.50
PDE2A O00408 1/20 0.49
HTR2A P28223 1/20 0.49
HTR2C P28335 1/20 0.49
KCNH2 Q12809 1/20 0.49
ROCK2 O75116 1/20 0.47
ROCK1 Q13464 1/20 0.47
SIGMAR1 Q99720 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8844465 0.91 PDCD1LG2 (0.52) CYP3A4CYP2C9CYP2D6CYP1A2CYP2C19
SCHEMBL14868702 0.91 PDCD1LG2 (0.52) CYP3A4CYP2C9CYP2D6CYP1A2CYP2C19
SCHEMBL6195713 0.84 DRD4 (0.59) DRD4DRD2DRD3SIGMAR1
SCHEMBL13490598 0.81 CYP2D6 (0.51) CYP3A4CYP2C9CYP2D6CYP1A2CYP2C19
SCHEMBL17898213 0.80 CYP3A4 (0.53) CYP3A4CYP2C9CYP2D6CYP1A2CYP2C19
SCHEMBL171619 0.80 PDE2A (0.55) CYP3A4CYP2D6CYP1A2CYP2C19ALDH1A1
SCHEMBL18239070 0.79 DRD4 (0.47) ALDH1A1DRD4
SCHEMBL30416250 0.79 DRD4 (0.48) DRD4DRD2DRD3
SCHEMBL28226193 0.79 CYP1A2 (0.66) CYP3A4CYP2D6CYP1A2CYP2C19ALDH1A1
SCHEMBL13490597 0.78 HRH2 (0.56) CYP3A4CYP2D6CYP1A2CYP2C19ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8530662-B2 Pyridyltetrahydropyridines and pyridylpiperidines, and method of manufacturing them FUJIFILM FINECHEMICALS CO., LTD (JP) 2013-09-10 US disclosed
US-8530662-B2 Pyridyltetrahydropyridines and pyridylpiperidines, and method of manufacturing them FUJIFILM FINECHEMICALS CO., LTD (JP) 2013-09-10 US disclosed
US-20100029947-A1 Pyridyltetrahydropyridines and Pyridylpiperidines, and Method of Manufacturing Them FUJIFILM FINECHEMICALS CO., LTD 2010-02-04 US disclosed
US-20100029947-A1 Pyridyltetrahydropyridines and Pyridylpiperidines, and Method of Manufacturing Them FUJIFILM FINECHEMICALS CO., LTD 2010-02-04 US disclosed
US-7632950-B2 Pyridyltetrahydropyridines and pyridylpiperidines and method of manufacturing them FUJIFILM FINECHEMICALS CO., LTD (JP) 2009-12-15 US disclosed
US-7632950-B2 Pyridyltetrahydropyridines and pyridylpiperidines and method of manufacturing them FUJIFILM FINECHEMICALS CO., LTD (JP) 2009-12-15 US disclosed
US-20070093528-A1 Pyridyltetrahydropyridines and pyridylpiperidines and method of manufacturing them FUJIFILM FINECHEMICALS CO., LTD (JP) 2007-04-26 US disclosed
US-20070093528-A1 Pyridyltetrahydropyridines and pyridylpiperidines and method of manufacturing them FUJIFILM FINECHEMICALS CO., LTD (JP) 2007-04-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100029947-A1 Pyridyltetrahydropyridines and Pyridylpiperidines, and Method of Manufacturing Them QDPR, HRH4, HRH2 CYP3A4 37/4885CYP2C9 203/4885CYP2D6 39/4885
US-20070093528-A1 Pyridyltetrahydropyridines and pyridylpiperidines and method of manufacturing them QDPR, HRH4, HRH2 CYP3A4 53/4885CYP2C9 247/4885CYP2D6 50/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.